INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Podrobná bibliografie
Hlavní autoři:	Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T
Médium:	Conference item
Vydáno:	2010

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
Autor: Madi, A, a další
Vydáno: (2010)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Autor: Adams, R, a další
Vydáno: (2009)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Autor: Adams, R, a další
Vydáno: (2009)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
Autor: Maughan, T, a další
Vydáno: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Autor: Adams, R, a další
Vydáno: (2011)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Autor: Madi, A, a další
Vydáno: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Autor: Madi, A, a další
Vydáno: (2012)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Autor: Maughan, T, a další
Vydáno: (2009)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Autor: Maughan, T, a další
Vydáno: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
Autor: Adams, R, a další
Vydáno: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
Autor: Maughan, T, a další
Vydáno: (2010)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Autor: Wasan, H, a další
Vydáno: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Autor: Adams, R, a další
Vydáno: (2008)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Autor: Wood, G, a další
Vydáno: (2017)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
Autor: Dae-Won Lee, a další
Vydáno: (2019-05-01)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Autor: Maughan, T, a další
Vydáno: (2010)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Autor: Seymour, M, a další
Vydáno: (2007)

Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer
Autor: Popov Ivan, a další
Vydáno: (2007-01-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Autor: Seymour, M, a další
Vydáno: (2007)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Autor: Seymour, M, a další
Vydáno: (2011)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Autor: Yeong Hak Bang, a další
Vydáno: (2021-03-01)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Autor: Iveson, T, a další
Vydáno: (2018)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
Autor: Taieb, J, a další
Vydáno: (2012)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Autor: Madi, A, a další
Vydáno: (2018)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
Autor: West, H, a další
Vydáno: (2018)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Autor: Maughan, T, a další
Vydáno: (2003)

Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator
Autor: Aderonke Abiodun, a další
Vydáno: (2024-10-01)

Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies
Autor: Chris Gale, a další
Vydáno: (2024-08-01)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
Autor: S Whyte, a další
Vydáno: (2010-10-01)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
Autor: J. M. Short, a další
Vydáno: (2023-09-01)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
Autor: Harrison, G, a další
Vydáno: (2000)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Autor: Smith, C, a další
Vydáno: (2013)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol
Autor: Antonio Avallone, a další
Vydáno: (2020-08-01)

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
Autor: N. S. Besova, a další
Vydáno: (2019-06-01)

Evolved bacterial resistance against fluoropyrimidines can lower chemotherapy impact in the Caenorhabditis elegans host
Autor: Brittany Rosener, a další
Vydáno: (2020-11-01)

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
Autor: Theodore J. Wigle, a další
Vydáno: (2021-07-01)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
Autor: Young Saing Kim, a další
Vydáno: (2017-01-01)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
Autor: Linda Cucciniello, a další
Vydáno: (2022-09-01)

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
Autor: Seid Hamzic, a další
Vydáno: (2020-11-01)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
Autor: Georgia Ragia, a další
Vydáno: (2023-09-01)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Podobné jednotky

Podobné jednotky